THAR
Tharimmune Inc.
NASDAQ: THAR · HEALTHCARE · BIOTECHNOLOGY
$2.04
+6.81% today
Updated 2026-10-28
Market cap
$177.09M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.68
Dividend yield
—
52W range
$1 – $9
Volume
0.8M
Tharimmune Inc. (THAR) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
0.00%
ROE
-2.25%
ROA
-1.00%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2019 | $0.00 | $-1.53M | — | — | — |
| 2020 | $0.00 | $-2.42M | — | — | — |
| 2021 | $0.00 | $-2.21M | — | — | — |
| 2022 | $0.00 | $-8.47M | — | — | — |
| 2023 | $0.00 | $-9.32M | — | — | — |
| 2024 | $0.00 | $-12.20M | — | — | — |
Frequently asked questions
How much free cash flow does THAR generate?
THAR produced $-10.90M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.